Long-term outcome for patients with early stage marginal zone lymphoma and mantle cell lymphoma

Abstract

In this study with prolonged follow up, we compared clinical outcome, including cause of death and incidence of second cancer, for patients with early stage extranodal marginal zone lymphoma (EMZL, 49 patients), nodal marginal zone lymphoma (NMZL, nine patients) and mantle cell lymphoma (MCL, 42 patients) with emphasis on potential benefit of radiotherapy. Radiotherapy was given to 40 patients with EMZL (nine had surgery only) and all NMZL patients. MCL patients received radiotherapy (17 patients), chemotherapy followed by radiotherapy (13 patients) or chemotherapy alone (12 patients). Compared to a matched control population no increased risk of second cancer or cardiovascular disease was observed. Radiotherapy alone was effective in EMZL and NMZL with low-relapse rates (20% and 33%) and a 10-year overall survival of 78% and 56%, respectively. High-relapse rate and inferior OS in MCL underline the need for extended staging with endoscopy and PET/CT and possibly for novel strategies.

Keywords:

• Marginal zone lymphoma
• mantle cell lymphoma
• radiotherapy
• early stage

Acknowledgements

We gratefully acknowledge Grethe Lauvvang and Jennifer Kerr for valuable secretarial assistance.

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article at http://dx.doi.org/10.1080/10428194.2016.1204653.

Funding information

Dlawer Abdulla Barzenje has been supported with grants from Ostfold Hospital Trust, Kalnes, Norway. Arne Kolstad and Harald Holte have both received a research grant from Norwegian Cancer Society.